ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ricolinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

31 träffar

Bibliografisk träff 2024-03-23

Hippocampal HDAC6 promotes POCD by regulating NLRP3-induced microglia pyroptosis via HSP90/HSP70 in aged mice.

Lin QC, Wang J, Wang XL, Pan C, Jin SW, Char S, Tao YX, Cao H, Li J.

Biochim Biophys Acta Mol Basis Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbadis.2024.167137

Bibliografisk träff 2024-01-17

HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.

Wen Y, Ye S, Li Z, Zhang X, Liu C, Wu Y, Zheng R, Xu C, Tian J, Shu L, Yan Q, Ai F, Ma J.

Cancer Immunol Immunother · research-article; journal article · DOI 10.1007/s00262-023-03624-y

Bibliografisk träff 2023-06-15

Ricolinostat is not a highly selective HDAC6 inhibitor.

Médard G, Sheltzer JM.

Nat Cancer · letter; comment · DOI 10.1038/s43018-023-00582-3

Bibliografisk träff 2023-06-15

Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor.

Silva J, Yu J, Yu J, Kalinsky K.

Nat Cancer · letter; comment · DOI 10.1038/s43018-023-00583-2

Bibliografisk träff 2023-01-01

Spinal HDAC6 mediates nociceptive behaviors induced by chronic constriction injury via neuronal activation and neuroinflammation.

Sun K, Zhang H, Zhang T, Sun N, Hao J, Wang Z, Gao C.

Mol Pain · research support, non-u.s. gov't; research-article; journal article · DOI 10.1177/17448069231218352

Bibliografisk träff 2022-12-30

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.

Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J.

Nat Cancer · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/s43018-022-00489-5

Bibliografisk träff 2022-12-28

HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling.

Vong P, Messaoudi K, Jankovsky N, Gomilla C, Demont Y, Caulier A, Jedraszak G, Demagny J, Djordjevic S, Boyer T, Marolleau JP, Rochette J, Ouled-Haddou H, Garçon L.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.17559

Bibliografisk träff 2022-12-14

Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases.

Li J, Yu M, Fu S, Liu D, Tan Y.

Front Pharmacol · published erratum; correction · DOI 10.3389/fphar.2022.1117936

Bibliografisk träff 2022-06-08

ACY-1215 suppresses the proliferation and induces apoptosis of chronic myeloid leukemia cells via the ROS/PTEN/Akt pathway.

Qin Y, Liang Y, Jiang G, Peng Y, Feng W.

Cell Stress Chaperones · research-article; journal article · DOI 10.1007/s12192-022-01280-2

Bibliografisk träff 2022-05-16

Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases.

Li J, Yu M, Fu S, Liu D, Tan Y.

Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2022.907981

Bibliografisk träff 2022-02-22

Effect of ACY-1215 on cytoskeletal remodeling and histone acetylation in bovine somatic cell nuclear transfer embryos.

Gao S, Wang Z, Ma J, Wang J, Xing X, Shen C, Niu Z, Li H, Zhang S, Zhang K, Gao J, Zhang Y, Wang Y.

Theriogenology · journal article · DOI 10.1016/j.theriogenology.2022.02.018

Bibliografisk träff 2022-01-05

HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation.

Chen C, Liu A, Lu Q, Luo L, Li J, Ke J, Liu Y, Feng X.

Chem Biol Interact · journal article · DOI 10.1016/j.cbi.2022.109803

Bibliografisk träff 2022-01-01

Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells.

Kim C, Lee S, Kim D, Lee DS, Lee E, Yoo C, Kim KP.

Anticancer Res · journal article · DOI 10.21873/anticanres.15505

Bibliografisk träff 2021-02-09

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.

Amengual JE, Lue JK, Ma H, Lichtenstein R, Shah B, Cremers S, Jones S, Sawas A.

Oncologist · other; journal article; research support, n.i.h., extramural · DOI 10.1002/onco.13673

Bibliografisk träff 2020-07-09

ACY‑1215, a HDAC6 inhibitor, decreases the dexamethasone‑induced suppression of osteogenesis in MC3T3‑E1 cells.

Wang N, Wang H, Chen J, Wang F, Wang S, Zhou Q, Ying J, Huang S, Wang P, Yuan F.

Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2020.11319

Bibliografisk träff 2019-09-30

Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.

Wang D, Wang B, Liu Y, Dong X, Su Y, Li S.

Neurochem Res · journal article · DOI 10.1007/s11064-019-02882-6

Bibliografisk träff 2019-08-21

Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.

Li L, Liu F, Huang W, Wang J, Wan Y, Li M, Pang Y, Yin Z.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2019.109357

Bibliografisk träff 2019-06-11

Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice.

Zhang WB, Zhang HY, Wang Y, Jiao FZ, Wang LW, Gong ZJ.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2019.00653

Bibliografisk träff 2018-12-01

ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB signaling pathways.

Cheng C, Shan W, Huang W, Ding Z, Cui G, Liu F, Lu W, Xu J, He W, Yin Z.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2018.11.017

Bibliografisk träff 2018-07-26

Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.

Cao J, Lv W, Wang L, Xu J, Yuan P, Huang S, He Z, Hu J.

Cell Death Dis · research-article; journal article · DOI 10.1038/s41419-018-0788-2

Bibliografisk träff 2018-07-17

Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.

Wu CP, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV.

Biochem Pharmacol · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.bcp.2018.07.018

Bibliografisk träff 2018-07-01

ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.

Wang F, Zhong BW, Zhao ZR.

J Biol Regul Homeost Agents · journal article

Bibliografisk träff 2018-05-11

The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.

Lee DH, Won HR, Ryu HW, Han JM, Kwon SH.

Int J Oncol · journal article · DOI 10.3892/ijo.2018.4405

Bibliografisk träff 2017-12-04

Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.

Porter NJ, Mahendran A, Breslow R, Christianson DW.

Proc Natl Acad Sci U S A · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1718823114

Bibliografisk träff 2017-11-06

Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway.

Zhang WB, Zhang HY, Jiao FZ, Wang LW, Zhang H, Gong ZJ.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2017.10.103

Bibliografisk träff 2017-07-26

An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease.

Yanda MK, Liu Q, Cebotaru L.

Am J Physiol Renal Physiol · research-article; journal article · DOI 10.1152/ajprenal.00186.2017

Bibliografisk träff 2016-12-28

ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.

Peng U, Wang Z, Pei S, Ou Y, Hu P, Liu W, Song J.

Oncol Rep · journal article · DOI 10.3892/or.2016.5340

Bibliografisk träff 2015-06-26

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-14-3068

Bibliografisk träff 2015-02-23

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/bjh.13315

Bibliografisk träff 2014-01-01

Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.

Zhang L, Liu C, Wu J, Tao JJ, Sui XL, Yao ZG, Xu YF, Huang L, Zhu H, Sheng SL, Qin C.

J Alzheimers Dis · research support, non-u.s. gov't; journal article · DOI 10.3233/jad-140066